Danish Medicines Agency to launch second reimbursement risk-sharing program

On Wednesday, pharmaceutical firms can apply to a trial scheme in Denmark where the public health system and private firms join forces to share the financial risks of expanding certain drug reimbursements.

Photo: Lægemiddelstyrelsen/PR

The Danish Medicines Agency is ready for another risk-sharing scheme concerning reimbursements for prescription drugs. The original program, which spanned three years and ended in 2021, was aimed at opening reimbursement access for patients in Denmark.

Through the program, the public healthcare system in Denmark covers costs for a fixed amount of patients who fulfill certain requirements, while the drugmaker is liable for payments should that number exceed the target population.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs